We found that 83.0% of LUAD patients and 66.67% of LUSC patients manifested as ADAR1high (83 cases and 32 cases, respectively), which indicated that most of the NSCLC patients had higher expression of ADAR1 (Figure 1B). This evidence concerns the gene ADAR and non-small cell lung carcinoma.